Quick Answer
MiNK Therapeutics, Inc. reported Net Income Loss of -$12.49 million for the year ending 2025.
- MiNK Therapeutics, Inc. showed a decrease of -15.9% in Net Income Loss from 2024 to 2025.
- This data is from MiNK Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$4.39 million | Q2 2020: -$4.27 million | Q3 2020: -$6.04 million | Q1 2021: -$3.85 million | Q2 2021: -$6.34 million | Q3 2021: -$14.27 million | Q1 2022: -$7.78 million | Q2 2022: -$6.11 million | Q3 2022: -$6.33 million | Q1 2023: -$5.69 million | Q2 2023: -$6.20 million | Q3 2023: -$5.12 million | Q1 2024: -$3.81 million | Q2 2024: -$2.70 million | Q3 2024: -$1.81 million | Q1 2025: -$2.77 million | Q2 2025: -$4.24 million | Q3 2025: -$2.89 million.
- Over the full 6 years of available data (2020 to 2025), MiNK Therapeutics, Inc.'s Net Income Loss has grown by 23.1%.
- Historical annual values: Fiscal year 2025: -$12.49 million | Fiscal year 2024: -$10.78 million | Fiscal year 2023: -$22.46 million | Fiscal year 2022: -$27.99 million | Fiscal year 2021: -$30.21 million | Fiscal year 2020: -$16.24 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: